MedPath

Clinical Validation of the Apollo Daily Disposable Soft Contact Lenses

Completed
Conditions
Myopia
Registration Number
NCT05035017
Lead Sponsor
Coopervision, Inc.
Brief Summary

The purpose of this study was to confirm the design specifications of a Test lens and validate its clinical performance.

Detailed Description

This was a double-masked, randomized, bilateral two-day crossover, dispensing study design. Subjects were randomized to wear the Test lens or Control lens bilaterally in random order and on a daily wear, single-use basis for a period of 2 days each.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Has had a self-reported oculo-visual examination in the last two years.
  • Is at least 18 years of age and has full legal capacity to volunteer.
  • Has read and understood the information consent letter.
  • Is willing and able to follow instructions and maintain the appointment schedule.
  • Is an adapted soft contact lens wearer, having worn contact lenses for a minimum 4 weeks prior to the study
  • Has spectacle cylinder ≤1.00D in both eyes.
  • Has spherical contact lens power requirement between -1.00D and -6.00D in both eyes.
  • Has manifest refraction visual acuities (VA) equal to or better than logMAR equivalent of 20/20 in each eye.
  • Wears CLs in both eyes (monovision acceptable, but not monofit)
  • Has clear corneas and no active ocular disease.
  • Has not worn lenses for at least 12 hours before the examination
  • Is willing to wear the study contact lenses for a minimum 8 hours on at least two consecutive days for each study pair.
Exclusion Criteria
  • Has never worn contact lenses before.
  • Has any systemic disease affecting ocular health.
  • Is using any concomitant systemic or topical medications that will affect ocular health.
  • Has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses.
  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.
  • Has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars.
  • Is aphakic.
  • Has undergone corneal refractive surgery.
  • Is participating in any other type of eye-related clinical or research study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Overall Comfort With Lens2 days

Participants rated their overall comfort once after 2 days of wear a 0-100 integer scale, where 0=Cannot be tolerated and 100=Excellent comfort.

Secondary Outcome Measures
NameTimeMethod
Overall Lens Handling2 days

Participant response on overall handling (insertion, removal, and holding) of contact lenses assessed once after 2 days of wear, on the third day. Measured on a 0-100 integer scale, where 0=Cannot be managed, 100=Excellent handling.

Overall Vision Quality2 days

Participant response measured once after 2 days of wear on a 0-100 integer scale, where 0= Unacceptable, 100=Excellent Vision.

Overall Lens Fit Acceptance2 days

Measured once after 2 days of wear by investigator on lens fit alone (excludes comfort, vision, orientation) on a 0-4 scale, 0.25 steps, where 0=Can't be worn and 4=Optimum

Anterior Ocular Health - Corneal Staining Extent2 days

Assessed once after 2 days of wear with slit lamp biomicroscopy and graded on a 0-4 integer scale, where 0=No Staining and 4=\>45% of area. Lower values represented a better outcome, e.g., a grading value of 1 would represent less corneal staining than a grade of 4. Locations (central, nasal, temporal, superior, inferior) were graded separately.

Trial Locations

Locations (1)

Indiana University School of Optometry

🇺🇸

Bloomington, Indiana, United States

Indiana University School of Optometry
🇺🇸Bloomington, Indiana, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.